EverHint Signal — Momentum Swing: Aggressive Momentum — December 22, 2025

What This Signal Is (Quick)

Aggressive Momentum is the most selective swing strategy in the momentum suite. This isn't for the faint of heart—it's designed to capture the triple threat: stocks with explosive volume (2.0x+ average), extreme volatility (50%+ annualized), and strong momentum near 52-week highs.

Core Criteria:

• Volume thrust 2.0x+ — double the normal buying pressure, indicating serious institutional activity
• Volatility 50%+ — annualized volatility exceeding 50%, meaning these stocks can swing 3-5% daily
• Strong momentum — multi-timeframe price acceleration
• Holding period: 1-4 weeks (swing trading timeframe)
• Risk level: High

This strategy is not for conservative portfolios. These are the wildest momentum plays—the kind that can gain 10-20% in a week or reverse violently on a single headline. The strict filters mean you'll see very few signals (sometimes zero), but when they appear, they represent maximum conviction setups.

Who this is for: Aggressive traders comfortable with 5-10% intraday swings, willing to use tight stops, and seeking asymmetric risk/reward. If you prefer slow and steady, skip this one.

This is an experimental scanner. Signals are for educational and research purposes only.

How We Ranked Today (Reader Version)

Signals are ranked by composite quality score (0-100 scale). Given the extreme selection criteria, scores tend to be lower than standard breakout strategies—a score of 30+ here is equivalent to 70+ in the Breakout Standard variant. The bar is simply higher.

We've overlaid:

• Insider Net Flows (last 90 days) — calculated from open-market purchases minus sales only
• Days to Earnings — time until next earnings report
• Volume Thrust — current volume vs 20-day average (minimum 2.0x for this strategy)
• Volatility (vol63) — 63-day annualized volatility (minimum 50% for this strategy)

These signals are designed for educational use and back-testing. Always do your own due diligence.

🔥 Aggressive Momentum Signals

2 stocks triggered today. This is a highly selective scan—some days produce zero signals.

Field Notes

VICR (Vicor Corporation) — Score 30

• Power components manufacturer at fresh 52-week high ($111.02)
• Extreme volatility: 79.5% annualized (expect 5-7% daily swings)
• Strong volume thrust: 2.07x average, confirming institutional interest
• Explosive 63-day momentum: +102.9% over 63 days (more than doubled)
• Recent pullback: -0.4% over last 10 days (consolidation near highs)
• Relative strength: RS 0.263 vs SPY (26.3% outperformance over 21 days)
• Insider activity: Modest selling ($248K) from VP-level executives exercising options
• Market cap: $5.0B (mid-cap)
• Earnings: 58 days out (Feb 18, 2026 AMC) — enough runway for swing trade

ABVX (Abivax S.A.) — Score 0

• French biotech at fresh 52-week high ($138.72)
• Highest volume thrust: 2.37x average (37% above baseline)
• Volatility: 52.7% annualized (just meets the 50% minimum)
• Negative short-term momentum: -1.3% over 10 days, -1.9% over 21 days
• Explosive 63-day run: +68.7% over 63 days
• Relative strength: RS 0.188 vs SPY (18.8% outperformance over 21 days)
• Catalyst: Added to Nasdaq Biotechnology Index effective today (Dec 22, 2025)
• Insider activity: None reported
• Market cap: $9.1B (mid-cap)
• Earnings: No upcoming date — reduces event risk

Why Score 0?
ABVX's zero score reflects negative short-term momentum despite meeting volume and volatility thresholds. The scoring algorithm penalizes recent weakness. However, the Nasdaq Biotech Index addition is a major catalyst that could override technical concerns—passive ETF flows often create sustained buying pressure.

Recent Headlines

ABVX (Abivax):

• Nasdaq Biotechnology Index Addition (Dec 18): Effective today (Dec 22, 2025) prior to market open. CFO Didier Blondel called it "a significant milestone for Abivax." This typically drives passive ETF inflows from index-tracking funds.
• ECCO 2026 Conference (Dec 17): Announced acceptance of 22 abstracts evaluating obefazimod in inflammatory bowel disease, including oral presentation on preclinical anti-fibrotic findings. Strong clinical pipeline validation.
• Company Profile: Clinical-stage biotech focused on therapeutics that harness the body's natural regulatory mechanisms to stabilize immune response in chronic inflammatory diseases.

VICR (Vicor Corporation):

• No major news — Recent insider selling from VP-level executives (option exercises)
• Business: Designs, develops, and manufactures power component solutions for power systems (AC-DC and DC-DC converters, power modules)
• Recent Performance: +102.9% over 63 days, consolidating at highs

Field Notes

Volume Thrust Analysis:
Both signals exceed the 2.0x minimum, confirming this isn't noise:

• VICR: 2.07x (107% above 20-day average)
• ABVX: 2.37x (137% above 20-day average)

This level of volume typically indicates institutional accumulation, block trades, or algorithmic buying.

Volatility Context:
Both meet the 50%+ annualized volatility threshold:

• VICR: 79.5% vol63 — expect daily ranges of 5-7% (extreme)
• ABVX: 52.7% vol63 — expect daily ranges of 3-5% (high)

For perspective, the S&P 500 averages ~15-20% annualized volatility. These names are 4x+ more volatile.

Sector Distribution:

• Technology: 1 signal (VICR)
• Healthcare: 1 signal (ABVX)

No sector clustering—these are idiosyncratic plays, not broad sector rotation.

Insider Activity:

• VICR: -$248K net selling (VP Human Resources and VP-Corporate Controller sold after option exercises)
• ABVX: No insider activity reported

The VICR selling is modest and appears tax-related (option exercises followed by immediate sales). Not a major red flag.

% of 52W High:
Both at exactly 100%—fresh breakouts to new 52-week highs. This is the ideal entry zone for momentum strategies.

Score vs Reality:
Don't fixate on the low scores (30 and 0). Aggressive Momentum scores are inherently lower due to extreme volatility and momentum requirements. A score of 30 here is strong. A score of 0 (ABVX) reflects short-term weakness but doesn't account for today's Nasdaq index addition catalyst.

Vlad's Take (EverHint)

Market Context: Sunday December 22, 2025 close — S&P 500 +0.19%, Nasdaq -0.09%, Dow +0.31%. Mixed session with value slightly outperforming tech. The VIX closed at 14.12 (-6.86%), indicating low volatility and a complacent market environment. Small-caps (Russell 2000) gained 0.64%, outperforming the Nasdaq, suggesting risk-on appetite. Bitcoin -0.14%, Ethereum -0.23%. Overall: Mildly bullish, low-vol environment with sector rotation underway.

Strategy Implications:

Only 2 signals today tells you everything you need to know about how selective this strategy is. Most days, you'll get zero. When signals appear, they deserve attention.

What I'd do:

1. ABVX is the contrarian play. Score 0 screams "avoid," but the Nasdaq Biotech Index addition effective today changes the game. Passive ETF flows from index-tracking funds (e.g., IBB, XBI) will create sustained buying pressure over the next 5-10 trading days. This is a technical catalyst trade, not a fundamental bet. Entry: current levels or slight pullback to $135. Stop: $130 (4% below MA50). Target: $150-155 (retest of previous resistance or +8-12%). Hold 1-2 weeks maximum.

2. VICR is the pure momentum play. +102.9% over 63 days is parabolic. You're buying at the top, which violates classic investing rules, but that's the point of aggressive momentum—ride the wave until it breaks. The 10-day consolidation (-0.4%) suggests coiling action. If it breaks above $112, next leg could target $120-125. Entry: breakout above $112 on volume. Stop: $105 (below MA10). Hold: 2-4 weeks. Exit on first sign of volume exhaustion.

3. Position sizing is critical. With 79.5% volatility (VICR) and 52.7% volatility (ABVX), these can swing 5-10% in a day. If you normally risk 1% per trade, consider 0.5% here. If you trade $100K, allocate $5K-10K max per position. One bad day can wipe 7-10% of your position—you need room to breathe.

4. Low VIX = false sense of security. The market VIX is 14.12 (low), but VICR's implied volatility is 79.5% (extreme). Don't let the calm S&P lull you into complacency. These stocks move independently of the index.

5. Earnings proximity: VICR reports Feb 18 (58 days out), giving you ample runway for a 2-4 week swing trade. ABVX has no upcoming earnings, which is ideal—one less binary event to worry about.

6. Failed breakout protocol: If either stock closes below its MA50 on heavy volume, exit immediately. Aggressive momentum plays don't get second chances. Breakouts either work fast or fail spectacularly.

Risk Management:

This isn't a "buy and hold" strategy. You're trading volatility and momentum, not building a retirement portfolio. Rules:

• Max hold period: 4 weeks
• Trailing stops: Use 5-7% trailing stops (given the volatility)
• Daily monitoring: Check positions daily—these can gap 5% overnight
• No averaging down: If it breaks, it breaks. Cut losses and move on.

The Honest Take:

Most traders shouldn't trade this strategy. It's designed for experienced momentum traders who understand that 9 out of 10 aggressive momentum plays fail or whipsaw. The 1 that works pays for the 9 losses and then some. If you can't stomach a 15% drawdown in a single position, stick to Breakout Standard or SMA crossovers.

But if you have the risk tolerance, ABVX's index addition catalyst is the rare setup where fundamentals (passive flows) align with technicals (breakout + volume). That's the edge.

✨ If this gave you insight, a quick like, share, or subscribe supports the continued work behind EverHint.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/